E
Tango Therapeutics, Inc.
TNGX
$1.21
-$0.06-4.72%
E
Sell
2/21/2025Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index and total return index.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index and total return index.
D
Sell
1/21/2025Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and valuation index.
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 1/21/2025 due to an increase in the volatility index and valuation index.
E
Sell
1/6/2025Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 1/6/2025 due to a substantial decline in the total return index, growth index and volatility index. Total revenue declined 41.6% from $19.88M to $11.61M, operating cash flow declined 41.44% from -$23.61M to -$33.39M, and earnings per share declined from -$0.2359 to -$0.2688.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 1/6/2025 due to a substantial decline in the total return index, growth index and volatility index. Total revenue declined 41.6% from $19.88M to $11.61M, operating cash flow declined 41.44% from -$23.61M to -$33.39M, and earnings per share declined from -$0.2359 to -$0.2688.
D
Sell
9/16/2024Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 9/16/2024 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 207.14% from $6.47M to $19.88M, operating cash flow increased 37.64% from -$37.86M to -$23.61M, and earnings per share increased from -$0.3505 to -$0.2359.
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 9/16/2024 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 207.14% from $6.47M to $19.88M, operating cash flow increased 37.64% from -$37.86M to -$23.61M, and earnings per share increased from -$0.3505 to -$0.2359.
E
Sell
7/29/2024Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 7/29/2024 due to a decline in the valuation index and volatility index.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 7/29/2024 due to a decline in the valuation index and volatility index.
D
Sell
7/12/2024Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 7/12/2024 due to an increase in the valuation index, total return index and volatility index.
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 7/12/2024 due to an increase in the valuation index, total return index and volatility index.
E
Sell
6/27/2024Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 6/27/2024 due to a decline in the growth index and valuation index. Operating cash flow declined 37.83% from -$27.47M to -$37.86M, EBIT declined 20.68% from -$35.01M to -$42.26M, and earnings per share declined from -$0.3164 to -$0.3505.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 6/27/2024 due to a decline in the growth index and valuation index. Operating cash flow declined 37.83% from -$27.47M to -$37.86M, EBIT declined 20.68% from -$35.01M to -$42.26M, and earnings per share declined from -$0.3164 to -$0.3505.
D
Sell
9/14/2023Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 9/14/2023 due to a noticeable increase in the total return index and volatility index.
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 9/14/2023 due to a noticeable increase in the total return index and volatility index.
E
Sell
8/30/2023Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and valuation index.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and valuation index.
D
Sell
8/9/2023Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 8/9/2023 due to a major increase in the growth index, total return index and volatility index. Total revenue increased 153.17% from $5.77M to $14.6M, operating cash flow increased 29.89% from -$34.91M to -$24.47M, and earnings per share increased from -$0.3176 to -$0.2344.
Tango Therapeutics, Inc. (TNGX) was upgraded to D- from E+ on 8/9/2023 due to a major increase in the growth index, total return index and volatility index. Total revenue increased 153.17% from $5.77M to $14.6M, operating cash flow increased 29.89% from -$34.91M to -$24.47M, and earnings per share increased from -$0.3176 to -$0.2344.
E
Sell
7/24/2023Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 7/24/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.63 to 6.22.
Tango Therapeutics, Inc. (TNGX) was downgraded to E+ from D- on 7/24/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.63 to 6.22.
D
Sell
3/14/2023Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and total return index.
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index.
D
Sell
11/29/2022Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 11/29/2022 due to an increase in the total return index and volatility index.
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 11/29/2022 due to an increase in the total return index and volatility index.
D
Sell
11/14/2022Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 11/14/2022 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 18.73% from -$25.2M to -$29.92M, the quick ratio declined from 9.36 to 7.7, and earnings per share declined from -$0.283 to -$0.3305.
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 11/14/2022 due to a substantial decline in the growth index, solvency index and valuation index. EBIT declined 18.73% from -$25.2M to -$29.92M, the quick ratio declined from 9.36 to 7.7, and earnings per share declined from -$0.283 to -$0.3305.
D
Sell
5/5/2022Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 05/05/2022.
Tango Therapeutics, Inc. (TNGX) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 12.54% from -$19.59M to -$22.05M, and total capital declined 7.07% from $372.59M to $346.25M.
Tango Therapeutics, Inc. (TNGX) was downgraded to D- from D on 4/20/2022 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 12.54% from -$19.59M to -$22.05M, and total capital declined 7.07% from $372.59M to $346.25M.
D
Sell
1/18/2022Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D from D+ on 1/18/2022 due to a large decline in the volatility index and total return index.
Tango Therapeutics, Inc. (TNGX) was downgraded to D from D+ on 1/18/2022 due to a large decline in the volatility index and total return index.
D
Sell
12/22/2021Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D+ from C- on 12/22/2021 due to a decline in the total return index.
Tango Therapeutics, Inc. (TNGX) was downgraded to D+ from C- on 12/22/2021 due to a decline in the total return index.
C
Hold
12/7/2021Upgraded
Tango Therapeutics, Inc. (TNGX) was upgraded to C- from D+ on 12/7/2021 due to an increase in the volatility index and valuation index.
Tango Therapeutics, Inc. (TNGX) was upgraded to C- from D+ on 12/7/2021 due to an increase in the volatility index and valuation index.
D
Sell
11/22/2021Downgrade
Tango Therapeutics, Inc. (TNGX) was downgraded to D+ from C- on 11/22/2021 due to a large decline in the growth index, volatility index and total return index. EBIT declined 329.52% from -$4.56M to -$19.57M, operating cash flow declined 185.9% from -$7.52M to -$21.49M, and total revenue declined 62.61% from $18.15M to $6.79M.
Tango Therapeutics, Inc. (TNGX) was downgraded to D+ from C- on 11/22/2021 due to a large decline in the growth index, volatility index and total return index. EBIT declined 329.52% from -$4.56M to -$19.57M, operating cash flow declined 185.9% from -$7.52M to -$21.49M, and total revenue declined 62.61% from $18.15M to $6.79M.
C
Hold
11/3/2021None
Tango Therapeutics, Inc. (TNGX) was downgraded to C- from U on 11/03/2021.
Tango Therapeutics, Inc. (TNGX) was downgraded to C- from U on 11/03/2021.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
